A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.
Status:
Completed
Trial end date:
2018-02-20
Target enrollment:
Participant gender:
Summary
The study is a First-in-Human, Phase I, randomized, double-blind, placebo-controlled, single
center study, evaluating single and multiple ascending oral doses of GLPG3067 and the
combination of GLPG3067 and GLPG2222 and the combination of GLPG3067,GLPG2222 and GLPG2737
given for 14 days in healthy women of non-childbearing potential.
The purpose of the study is to evaluate the safety and tolerability of single ascending oral
doses and multiple ascending oral doses of GLPG3067 given to healthy women of
non-childbearing potential compared to placebo, as well as of multiple oral doses of the
combination of GLPG3067/GLPG2222 compared to matching placebo for each compound and multiple
oral doses of the combination of GLPG3067/GLPG2222/GLPG2737 compared to matching placebo for
each compound.